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Isoliquiritigenin modulates miR-
374a/PTEN/Akt axis to suppress 
breast cancer tumorigenesis and 
metastasis
Fu Peng1,2,3, Hailin Tang1,4, Peng Liu4, Jiangang Shen1, Xinyuan Guan  5, Xiaofang Xie2,3, Jihai 
Gao2,3, Liang Xiong2,3, Lei Jia1, Jianping Chen1,2 & Cheng Peng2,3
Breast cancer is one of the most frightful causes of death among females worldwide. Accumulating 
evidence attached the importance of microRNAs negative regulation to tumorigenesis in breast cancer, 
suggesting novel cancer therapies targeting microRNAs modulation. Recent studies demonstrated 
that isoliquiritigenin could inhibit breast cancer cells proliferation and migration, but the underlying 
mechanism is still limited. In this study, the anti-cancer effects as well as the detailed mechanisms 
of isoliquiritigenin were explored. The results proved that isoliquiritigenin could negatively regulate 
breast cancer growth through the induction of apoptosis. We also verified the anti-cancer effect of 
isoliquiritigenin on migration and invasion, and identified highly expressed miR-374a as one of the main 
microRNAs down-regulated by isoliquiritigenin treatment in breast cancer. Further study displayed 
that isoliquiritigenin increased PTEN expression through the decrease of miR-374a expression to inhibit 
the aberrant Akt signaling. Our findings suggest isoliquiritigenin as a novel anti-cancer candidate 
significantly regulating miR-374a/PTEN/Akt axis in microRNA-based breast cancer therapies.
Breast cancer, especially triple negative breast cancer (TNBC), is considered as one of the most aggressive cancers 
and one of the major causes of mortality among female worldwide. Although the early-detection system and 
multidisciplinary treatments have improved, breast cancer incidences and recurrence ratios remain unsatisfac-
tory, especially for developed countries1. In 2015, it was reported by the Breast Cancer Research Foundation that 
emerging 231,840 American women had been diagnosed with invasive breast cancer2. Hence, developing novel 
biomarkers and approaches focusing on breast cancer prevention and treatment has become an urgent issue.
In the recent decades, accumulating evidences indicated that small non-coding RNA molecules (i.e., miR-
NAs), as negative gene regulators with the ability to induce targeted mRNAs degradation and/or translational 
inhibition, could govern cell proliferation, cell migration, cell invasion, cell differentiation and angiogenesis in 
the development and progression of breast cancer3–7. Recently, miRNA profiling demonstrated that miR-374a 
was highly overexpressed in several different types of human cancer, including head and neck cancer, follicular 
lymphoma, and small cell lung cancer8–10. In esophageal cancer, high expression of miR-374a could promote 
proliferation via directly targeting Axin2, an inducer of apoptosis11. In breast cancer, miR-374a was remarkably 
upregulated in metastatic breast cancer cells through the direct target of WIF1, Wnt5a, and PTEN, which is a key 
suppressor of oncogenic PI3K/Akt signaling in breast cancer, especially in TNBCs, and positively correlated to 
disease-free survival ratio and negatively correlated to invasive grade12, 13. Interestingly, higher expression of miR-
374a was correlated with better prognosis among TNBC patients14. However, whether miR-374a could promote 
breast cancer proliferation is still unclear.
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Since miRNAs, with capacity of single miRNA interacting with multiple mRNAs, are the most substantial reg-
ulatory genes on the gene expression network, reports in increasing number initially concentrate on developing 
miRNA-based strategies for cancer therapies15–17. Well-known tumor suppressor miRNAs have been gradually 
assessed in clinical trials is of benefit to cancer patients. For an instance, miR MRX34 used in a phase-I clinical 
trial (NCT01829971) for liver cancer therapy is underway18. Recently, attention had shifted towards traditional 
Chinese medicine (TCM) for the treatment of multiple malignancy-related processes because of the low toxicity 
and high tolerability, and single compounds from TCM are gaining acceptance as potently potential anticancer 
agents targeting oncogenic miRNAs (e.g., berberine, curcumin, and resveratrol)19–21. Isoliquiritigenin (ISL), a nat-
ural flavonoid majorly derived from the root of licorice, possesses anti-cancer activities at multistage carcinogene-
sis processes, including proliferation suppression, cell cycle arrest, angiogenesis inhibition, metastasis obstruction 
and apoptosis induction in various types of cancer22–24. In our pervious work, ISL showed an essential inhibitory 
effect on breast cancer through the inhibition of angiogenesis, the activation of autophagy, and the repression of 
breast cancer stem cells with minimal effects on the proliferation of the MCF-10A normal human mammary epi-
thelial cell line and normal tissues25–28. Additionally, its inhibitory effect on breast cancer growth and migration 
has been reported currently. ISL induced growth suppression and apoptosis in vitro and in vivo via repressing 
Arachidonic acid metabolic network and inactivating Akt pathway29. Its anti-migratory effect was confirmed 
in MDA-MB-231 cells through the reduction of VEGF secretion and the inhibition of PI3K/Akt expression30. 
Although ISL limited breast cancer proliferative and migratory ability, its suppressive effect on breast cancer 
metastasis and underlying mechanisms on PTEN/Akt signaling deserve further investigation.
In the present study, we addressed the role of ISL on mitochondria-based apoptosis induction and metastasis 
suppression of breast cancer in vitro and in vivo. Microarray analysis further revealed that miR-374a was one of 
the primary targets of ISL and negatively correlated to the pro-apoptotic effect and anti-metastatic effect of ISL. 
Notably, ISL-induced apoptosis and metastatic suppression was partly dependent on the increase of PTEN, which 
was the direct target of miR-374a ensured by luciferase assay. Taken together, our results unearthed a novel func-
tion of ISL as a natural miR-374a inhibitor to suppress breast cancer tumorigenesis and metastasis by regulating 
the aberrant Akt signaling.
Results
ISL inhibits cell proliferation and induces apoptosis of breast cancer cells. To determine whether 
ISL suppressed breast cancer cells, we tested the effects of ISL on the growth of human breast carcinoma cells 
using MTT assay. After ISL 24 h, 48 h, 72 h treatment, the cell viability was assessed. ISL treatment resulted in a 
dose-dependent inhibition of cell viability, with IC50 of 32.66 μM and 22.36 μM for 24 h treatment on MCF-7 and 
MDA-MB-231, respectively. At the dose of 6.25 μM, ISL did not affect the viability of MCF-7 and MDA-MB-231 
cells. ISL at 25 μM dramatically inhibited the breast cancer cells growth and induced a time-dependent decrease 
of cell numbers (P = 0.002, and P < 0.0001, respectively) (Fig. 1A). Further study demonstrated that ISL also 
displayed an inhibitory effect on primary culture of breast cancer proliferation (see Supplementary Fig. S1). The 
results from flow cytometry (i.e, Annexin V-FITC and propidium iodide (PI) staining) determined that ISL at low 
concentration did not manifest significant effect on apoptosis in breast cancer cells, while the effect of ISL at 25 μM 
and 50 μM was, at least mostly, through inducing apoptosis (For early apoptosis, P = 0.0038, and P = 0.0031, 
respectively, and for late apoptosis, P = 0.127, and P < 0.0001, respectively with ANOVA test) (Fig. 1B,C). 24 h ISL 
treatment significantly decreased Bcl-2 expression and increased Bax expression in a dose-dependent manner 
of in a range from 6.25 to 50 μM (For Bcl-2, P = 0.0302 and P = 0.0032, respectively, and for Bax, P = 0.003 and 
P = 0.0471, respectively with ANOVA test). We also measured cleavage of caspase-9 and the release of cytochrome 
c (Cyt C) from the mitochondria. The content of cytoplasmic Cyt C and cleaved caspase-9 were dose-dependently 
increased in MCF-7 and MDA-MB-231 cells by ISL treatment for 24 h (Fig. 1D,E). Thus, we chose ISL for further 
mechanism exploration of cell motility study at 6.25 μM and cell apoptosis study at 25 μM.
ISL suppresses breast cancer growth and lung metastasis in vivo. We used MMTV-PyMT mice 
model to further elucidate the in vivo anti-cancer effect of ISL on breast cancer growth and metastasis. Since it 
has been acknowledged that MMTV-PyMT female mice could develop palpable luminal-type mammary tumors 
metastasizing to the lung in or after the 10th week31, 32, ISL (50 mg/kg/d) were administered to the mice at 4th week 
from birth through oral intake, and at the 11th week of ISL treatment, mice had been sacrificed and tumors had 
been dissected from mice. Mammary tumors in vehicle group demonstrated a more hemorrhagic appearance 
than ISL treatment group, while the average size of ISL-treated tumors was dramatically smaller than that of 
vehicle group (Fig. 2A). Further histopathologic analysis indicated that both groups displayed typical features 
of malignancy, although less metastatic nodules were visible in ISL-treated group (Fig. 2B). The mean of tumor 
weight and tumor burden were considerably reduced after ISL administration for 11 weeks (Fig. 2C,D), and the 
survival span and ratio of MMTV-PyMT mice were prolonged with ISL treatment (Fig. 2E). No significant change 
of morphology was found out on normal tissues treated with ISL (see Supplementary Fig. S2). MMP7 is a matrix 
metallopeptidase involved in invasion and metastasis in multiple cancers including breast cancer33–35. Further 
IHC staining using anti-Bax and anti-MMP-7 revealed that the expression of Bax was substantially increased with 
ISL treatment, and MMP-7 expression was remarkably decreased, respectively (Fig. 2F). Collectively, these data 
manifest that ISL has a remarkable inhibitory effect on breast cancer tumorigenesis and pulmonary metastasis.
ISL reduces overexpressed miR-374a in breast cancer cells. Microarray was performed to analyze 
the miRNA expression at least 1.5 fold change regulated by ISL. 24 miRNAs expression were markedly altered in 
both MCF-7 and MDA-MB-231 cells cultured with ISL (25 μM) for 24 h (Fig. 3A). Out of the miRNAs screened, 
1 miRNA was consistently up-regulated and 20 miRNAs were steadily down-regulated after ISL interference 
(Fig. 3B). Data downloaded from array express (https://www.ebi.ac.uk/arrayexpress/) and developed in Università 
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Figure 1. Effect of ISL on cell proliferation and apoptosis in breast cancer cells. (A) Cell viability of MCF-7 and 
MDA-MB-231 after 24 h, 48 h, 72 h ISL treatment. (B) Representative images of induction of apoptosis in breast 
cancer cells determined by Flow cytometry analysis cultured with ISL (12.5, 25, 50 μM) for 24 h. (C) Percentages 
of early apoptotic cells and late apoptotic cells in different dose of ISL intervention according to Flow cytometry 
assay analysis. (D,F) Western blot analysis of Bcl-2, Bax, Cleaved Caspase-9, in MCF-7 and MDA-MB-231 after 
24 h ISL treatment. The full-length blots were presented in the Supplementary Fig. 7. (E) Western blot analysis 
of Cyt C release in breast cancer cells after 24 h ISL interference. The full-length blots were presented in the 
Supplementary Fig. 8. Data represent the mean ± s.d. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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di Ferrara demonstrated that miR-374a was reliably remarkably up-regulated in breast cancer patient tissues 
compared with the marched normal tissues among 20 miRNA differences analyzing with Morpheus (https://
software.broadinstitute.org/morpheus/) (see Supplementary Fig. S3). In situ hybridization analysis further con-
firmed the up-regulation of miR-374a in breast cancer patients (Fig. 3C). The expression of miR-374a expression 
was examined in 39 breast cancer tissue samples, and high level of miR-374a was associated with the clinical 
Figure 2. ISL inhibits tumorigenesis and metastasis in MMTV-PyMT transgenic mice. (A) Representative 
images of solid tumors collected from vehicle group and ISL treatment group (50 mg/kg/d). (B) Representative 
micromorphology of the dissected tumors and lungs with HE staining in 100-fold magnification. (C) Scatter 
plots of individual tumors with mean weights at the end point of ISL treatment (n = 6). (D) Data about tumor 
burden of mice from vehicle and ISL-treated (n = 6). (E) Kaplan-Meier curve of mice survival in two different 
groups after ISL administration (n = 6). (F) IHC staining analysis of Bax and MMP-7 in vehicle tumor tissues 
and ISL-treated tumor tissues. Data represent the mean ± s.d. **P < 0.01.
www.nature.com/scientificreports/
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Figure 3. MiR-374a is highly expressed and attenuated by ISL in breast cancer. (A,B) Microarray analysis 
of miRNAs differences after 24 h ISL treatment in MCF-7 and MDA-MB-231. (C) ISH analysis of miR-374a 
expression in tumor tissues and matched normal tissues from breast cancer patients. (D) qRT-PCR analysis 
of miR-374a levels in human cancer cell lines and spontaneously immortalized MCF-10A cells. (E) qRT-PCR 
analysis of differently expressed miR-374a levels at the indicated concentrations of ISL.
Variable Number of cases
miR-374a
High Low P value
Age (years)
  ≥50 18 11 7 0.802
  <50 21 12 9
Pathologic grade
  1, 2 25 16 9 0.201
  3 14 6 8
Clinical stage
  Ι, ΙΙ 25 11 14 0.037
  ΙΙΙ 14 11 3
Lymph node status
  Metastasis 19 12 7 0.408
  No metastasis 20 10 10
Table 1. Relationship between miR-374a level and clinicopathologic parameters of breast cancer.
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stage (P = 0.037) (Table 1). Findings from qRT-PCR analysis displayed that miR-374a was highly expressed in 
breast cancer cell lines and breast, especially for highly metastatic MDA-MB-231 (Fig. 3D, P = 0.0323, P = 0296, 
and P = 0.001, respectively). Using qRT-PCR, we validated that ISL decreased miR-374a expression in a 
dose-dependent manner (Fig. 3E), indicating miR-374a was a highly breast cancer-associated oncogenic miRNA 
modulated by ISL intervention.
ISL triggers apoptosis through the down-regulation of miR-374a in breast cancer cells. Using 
Real-time PCR, we confirmed the transfection of miR-374a into breast cancer cells and the down-regulation by 
ISL interference (Fig. 4A). Then, apoptotic cells percentages were analyzed through TUNEL staining. The results 
showed that the suppression of miR-374a by ISL treatment resulted in a significant increase of the number of 
TUNEL positive cells (P = 0.0303, and P = 0.0156, respectively), while the overexpression of miR-374a decreased 
the percentage of TUNEL positive cells (Fig. 4B,C). In addition, PCR results further revealed that miR-374a 
mimic decreased BAX expression, and increased BCL-2 expression on the mRNA level, while ISL reversed the 
anti-apoptotic effect of miR-374a in both MCF-7 and MDA-MB-231 cells (Fig. 4D), suggesting that miR-374a 
plays an essential role in the responses to ISL exposure in breast cancer cells.
Figure 4. ISL induces apoptosis by regulating miR-374a. (A) qRT-PCR analysis of expression levels of miR-
374a in miR-NC and miR-374a transfection groups treated with vehicle/ISL for 24 h. (B) Representative images 
of apoptotic cells determined by TUNEL assay in breast cancer cells after 24 h treatment. (C) Percentages 
of TUNEL positive cells in MCF-7 and MDA-MB-231. (D) qRT-PCR analysis of the effect of miR-374a 
interference on BCL-2 and BAX mRNA expression treated with ISL. Data represent the mean ± s.d. *P < 0.05, 
**P < 0.01.
www.nature.com/scientificreports/
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ISL inhibits miR-374a expression and suppresses migration and invasion of MDA-MB-231. 
Although ISL displayed a significant anti-migration effect on MDA-MB-231 in the pervious reports25, 30, the 
detailed mechanisms of its effect on anti-migration and anti-invasion are still unclear. The effect of ISL on migra-
tion of MDA-MB-231, with or without the miR-374a interference, was determined by wound healing assay, and 
confirmed by chamber migration assay. After 24 h exposure, ISL-treated cells, whether transfected with miR-374a 
mimic or miRNA mimic negative control (miR-NC), demonstrated a noticeable delay of responses to moving 
into wound area, compared with control group (Fig. 5A,C). The results from chamber migration assay showed 
the inhibitory effect of ISL were at least partly blocked by miR-374a transfection (Fig. 5B,D). Cells invasiveness 
assessed by transwell coated with Matrigel at 24 h showed similar inhibition by ISL and similarly revealed the 
interference of miR-374a in the inhibitory effect of ISL on cell invasive ability (Fig. 5C,E). As for MCF-7, ISL did 
not display the inhibitory effect on migration and invasion at the dose of 6.25 μM (see Supplementary Fig. S4). 
As for primary culture of breast cancer invasion, ISL showed an obvious inhibitory effect (see Supplementary 
Fig. S5). Taken together, ISL suppresses the migratory and invasive capacities of MDA-MB-231 through the dra-
matic suppression of miR-374a.
ISL regulates miR-374a/PTEN/Akt/β-catenin axis. TargetScan and Microrna.org software predicted 
one of the main targets of miR-374a was PTEN, the potent inhibitor of Akt pathway. Dual luciferase reporter 
assay confirmed the direct interaction of miR-374a and its predicted binding sites of 3′UTR region of PTEN 
(Fig. 6A). To evaluate the effect of miR-374a down-regulated by ISL on PTEN expression, we tested PTEN mRNA 
expression after ISL intervention. As shown in Fig. 6B, the increase of PTEN mRNA level by ISL was remarkable 
at 24 h point, and the up-regulated effect was at least partly alleviated by miR-374a mimic pretreatment (Fig. 6C). 
Western blot analyses confirmed the amplified of PTEN expression by ISL and displayed that ISL inhibited Akt 
and GSK3β phosphorylation, resulting in a decrease of β-catenin expression. Additionally, ISL-induced Akt/
GSK3β/β-catenin inhibition was partly reversed with miR-374a mimic transfection (Fig. 6D). The in vivo data 
were in consistent with in vitro results. ISL considerably increased PTEN expression and decreased β-catenin 
expression determined by IHC staining (Fig. 6E). Altogether, miR-374a is the functionally relevant effector of 
PTEN/Akt/β-catenin modulation by ISL.
Modulation of PTEN expression affects ISL-induced apoptosis and invasion inhibition. We 
used qRT-PCR to confirm the down-regulation of PTEN by siRNA PTEN and up-regulation of PTEN by ISL, 
and siRNA negative control (siRNA-NC) was used as the siRNA transfection control. (Fig. 7A). The results of 
qRT-PCR analysis also demonstrated that the decrease of PTEN would considerably block the BAX mRNA 
increase by ISL treatment (Fig. 7B). The pro-apoptotic effect and anti-invasive effect of ISL were also affected after 
the decrease of PTEN expression (Fig. 7C,D,E,F). Additionally, after transfected with siRNA PTEN, the effect 
of ISL on biomarkers in apoptosis on protein levels were also partly reversed (Fig. 7G). Collectively, PTEN, the 
suppressor of Akt pathway, is the essential responder to ISL induced apoptosis and invasion inhibition on breast 
cancer cells.
Discussion
MiR-374a was first characterized as an oncogene in primary small cell lung cancer (NSCLC), and miR-374a over-
expression could promote cell migration and invasion, positively correlating to the poor disease-free survival in 
NSCLC10, 36. The oncogenic effect of miR-374a on tumor invasion and metastasis contributed to its identification 
as cancerogenesis promoter in breast cancer progression by activating WNT/β-catenin signaling12. Recently, miR-
374a has emerged as one of the major proliferative factors in carcinogenetic signaling. High expression of miR-
374a promoted cell proliferation in vitro and tumor growth in vivo in in gastric cancer by targeting SRCIN137. 
Overexpressed miR-374a in osteosarcoma remarkably accelerated cell proliferation by directly targeting AXIN2 
and FOXO1, and silencing miR-374a could induce G0/G1 and G1/S arrest in cell cycle38, 39, suggesting its role as 
a potential therapeutic target. Based on our study, we also found high expression of miR-374a in breast cancer 
cells and tumors from breast cancer patients. However, the effect of miR-374a on breast cancer tumorigenesis 
was still unclear. Thus, we conducted a legitimate study to explore the functional ability of miR-374a in breast 
cancer growth. Using microarray screening, we demonstrated that miR-374a was one of the major miRNAs 
down-regulated by ISL treatment. The results were confirmed by RT-qPCR in a dose-dependent manner in both 
breast cancer cell lines and primary culture of breast cancer (see Supplementary Fig. S6). The decrease of miR-
374a by ISL interference was in accordance with the inhibition of breast cancer growth and invasion. Also, our 
data supported that overexpressing miR-374a could at least partly reverse the inhibitory effect of ISL on cell 
mobile ability and the pro-apoptotic effect on cell dearth. Hence, our study clarified for the first time that natural 
compound ISL could induce apoptosis and inhibit metastasis by down-regulating miR-374a.
Akt pathway promotes cell survival as one of the major anti-apoptotic factors through the block of extracel-
lular signal induced apoptosis40. Likewise, Akt signaling serves as a key activator of cell migration and invasion 
by phosphorylating a range of intracellular proteins41. Also, overexpression of pAkt was negatively associated 
with overall survival and disease-free survival of breast cancer patients42. Recently, ISL was reported as a prom-
ising inhibitor on Akt signaling in breast cancer29, 30. Therefore, we designed rationale experiments to investigate 
the underlying mechanisms involved Akt signaling pathway regulated by ISL. We collected ISL-treated MCF-7 
and MDA-MB-231 cells and examined the phosphorylation of Akt through western blot analysis. Based on the 
results, Akt inhibition by ISL was in consistent with miR-374a down-regulation by ISL, indicating the role of 
miR-374a as one of the up-streams regulating Akt pathway. Our data manifested that ISL could promote PTEN 
expression in vitro and in vivo. Further study displayed that miR-374a could negatively regulate PTEN, the tumor 
suppressor of Akt signaling, through the direct binding with 3′ UTR of PTEN mRNA. Whether miR-374a can 
post-transcriptionally modulate PTEN needs to be further studied. The PTEN down-regulation by miR-374a and 
www.nature.com/scientificreports/
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up-regulation by ISL were also confirmed through RT-qPCR and western blotting. Our findings indicated that 
ISL could down-regulate miR-374a, the negative regulator of PTEN, to suppress the significant oncogenic Akt 
signaling pathway.
Although our pervious study demonstrated that ISL and its derivatives inhibited breast cancer proliferation 
significantly43, studies examining the anti-cancer effect on mitochondrial-based apoptosis involving the release of 
Figure 5. Pretreatment of miR-374a in MDA-MB-231 attenuates the responses to ISL. (A) Representative 
images of wound healing assay in miR-NC and miR-374a mimic transfected groups after 24 h ISL treatment. (B) 
Chamber migration and invasion assay analysis of the effect of miR-374a transfection on breast cancer motile 
ability with ISL interference. (C) Percentages of closures of the wound in miR-374a-modulated MDA-MB-231 
cells by 24 h exposure to ISL. (D,E) Percentages of the number of cells located on the lower side of chambers and 
Matrigel-coated chambers in the presence of ISL with miR-374a interference. Data represent the mean ± s.d. 
*P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Cyt C are very limited. Our data showed that ISL could dose-dependently increase the ratio of apoptotic cells after 
24 h treatment. Interestingly, early apoptosis accounted for the majority of MCF-7 apoptotic cells, while ISL could 
induce a dramatic late apoptosis in MDA-MB-231, implying that MDA-MB-231 was more sensitive to response 
to ISL administration. Whether ISL could serve as a novel anti-cancer drug candidate with a more effective inhib-
itory effect on TNBCs needs to be further investigated. The western blot analysis exhibited that ISL could enlarge 
the percentage of released Cyt C in the cytoplasm with an increase of cleaved caspase-9 expression. The activated 
Akt could directly suppress proteolytic activity of caspase-9 via phosphorylating the protein44. These findings 
indicated that ISL could inactivate Akt pathway to enhance the activity of caspase-9, the positive regulator of Cyt 
C release in intrinsic apoptosis pathway.
In summary, our study exerted that ISL, a natural flavonoid, is a potent inhibitor of miR-374a in breast cancer. 
ISL inhibited cell proliferation and migration by down-regulating miR-374a expression, which negatively regulated 
Figure 6. MiR-374a/PTEN/Akt axis is involved in ISL inhibition of breast cancer. (A) Dual luciferase reporter 
assay analysis of the effect of miR-374a expression on 3’UTR of PTEN in 293 T cells. (B) qRT-PCR analysis of 
miR-374a targeted gene expression at the indicated time points in the presence of ISL. (C) qRT-PCR analysis 
of PTEN mRNA expression in normal and miR-374a-overexperssing breast cancer cells interfered with ISL. 
(D) Western blot analysis of miR-374a function on PTEN up-regulation, Akt inhibition, GSK3β suppression, 
and β-catenin down-regulation by ISL. The full-length blots were presented in the Supplementary Fig. 9. (E) 
Representative images of IHC analysis of PTEN and β-catenin expression in vehicle and ISL-treated tumors.
www.nature.com/scientificreports/
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Figure 7. Deletion of PTEN expression restricts the anti-cancer effect of ISL on breast cancer cells. (A) qRT-
PCR analysis of PTEN mRNA expression in siRNA-NC and siRNA PTEN transfection groups after 24 h ISL 
treatment. (B) qRT-PCR analysis of BAX mRNA expression in siRNA-NC and siRNA PTEN transfection 
groups with ISL interference. (C) Representative images of induction of apoptosis in breast cancer cells 
determined by Flow cytometry analysis after 24 h ISL intervention. (D) Chamber invasion assay analysis of the 
effect of siRNA PTEN transfection on breast cancer motile ability with ISL treatment for 24 h. (E) Percentages 
of apoptotic cells after ISL treatment with siRNA PTEN intervention. (F) Percentages of the number of cells 
invading in the ISL treatment with siRNA PTEN interference. (G) Western blot analysis of PTEN function on 
Bcl-2 down-regulation and Bax up-regulation by ISL. The full-length blots were presented in the Supplementary 
Fig. 10. Data represent the mean ± s.d. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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PTEN, resulting in the induction of apoptosis and invasive inhibition through the inactivation of Akt pathway. 
These data provide novel insights into the function of miR-374a regulating breast cancer tumorigenesis, and fur-
ther suggest a potential application of ISL as a miR-374a naturally inhibition candidate in breast cancer therapy.
Materials and Methods
Chemicals and Reagents. ISL was purchased from Alpha Aesar (MA, USA). Bovine serum albumin (BSA) 
Eosin Y, and Hematoxylin were purchased from Sigma (St. Louis, MO). All other reagents were obtained from 
standard commercial sources.
Cell culture. MDA-MB-231, MCF-7, BT474, 4T1, MCF-10A and 293 T were obtained from the American Type 
Culture Collection (ATCC, USA) and maintained in a humidified incubator with 5% CO2 at 37 °C. MDA-MB-231, 
BT474 and 293 T were cultured in high glucose DMEM media, while MCF-7 and 4T1 were cultured in RPMI 
1640 media, supplemented with 10% FBS and 1% penicillin and streptomycin (Gibco, Life Technologies, Lofer, 
AU). Spontaneously immortalized MCF10-A was cultured in keratinocyte serum-free medium (Gibco, Life 
Technologies, USA). Primary breast cancer was isolated from the distant metastatic position of a Luminal A breast 
cancer patient (Ethic approval obtained from Ethics Committee of Sun Yat-sen University Cancer Center, YB2016-
002-03). The written informed consent was obtained. The corresponding experimental protocols were performed 
in accordance with guidelines of the Sun Yat-sen University Cancer Center (Guangzhou, China).
Cell viability analysis. 5 × 103 cells/well were seeded in 96-well plates and incubated in presence of ISL 
at different dosages for 24 h, 48 h and 72 h. After treatment, 10 μl CCK-8 reagent (Biotool, Selleck Chemicals, 
Houston, USA) was added to the test well with 100ul cultured media and went through 3 h incubation in the 
incubator. Cell viability was recorded according to the absorbance at 450 nm by an ELISA plate reader. Triplicate 
experiments were performed independently.
Flow cytometry analysis. Apoptotic cell percentages were determined by FITC-AnnexinV Apoptosis 
detection kit (BD Pharmingen, San Diego, CA, USA) as the manufacturer’s instructions. In brief, 5 × 105 cells/well 
were seeded in 6-well plates and incubated with ISL at the indicated concentrations for 24 h. After harvested, cells 
were resuspend into 1X Binding Buffer at a concentration of 1 × 106 cells/ml, and stained with FITC-conjugated 
Annexin V and PI in the dark. Triplicate experiments were performed independently. Stained samples were quan-
tified by FACSAria SORP (BD Biosciences, San Jose, CA), and analyzed by FlowJo Software.
TUNEL assay. Cell apoptosis dearth ratio was determined by TUNEL Apo-Green detection kit (Biotool, 
Selleck Chemicals, Houston, USA) as the manufacturer’s protocol. Briefly, monolayer cells were culture on the 
glass coverslips and, after the proper treatment, cells were fixed with 4% paraformaldehyde. Samples were perme-
abilizd in 0.2% Triton X-100 solution and stained with reaction mixture. Glass coverslips with cells were mounted 
with ProLong Gold Antifade Reagent with DAPI (Cell Signaling Technology, Danvers, MA). Triplicate exper-
iments were performed independently. The images were detected by Axio Scope and analyzed by AxioVision 
Microscope 4.8 Software (Carl Zeiss AG, Jena, DE).
Wound migration assay. 3 × 105 cells/ml were plated into Culture-Insert (ibidi GmbH, Martinsried, DE) 
in 70 μl cell suspensions. After cell attachment, Culture-Insert was gently removed and cells were treated with 
different reagents for another 24 h. Images were taken before the treatment and after the treatment. The migratory 
inhibitory effect of ISL was determined by measuring the closure of the wound between cells. Triplicate experi-
ments were performed independently. The images were detected and analyzed by EVOS XL Core Imaging System 
(Invitrogen, Life Technologies, USA).
Chamber migration and invasion assays. Cell migratory ability was assessed by 6-well transwell cham-
bers (Corning Inc., Coring, USA) with 8-μm pore size. Briefly, 3 × 105 cells/well were seeded on the upper side 
with different concentrations of ISL and lower chamber was filled with media (10% FBS). After 24 h, migrated 
cells were stained by 0.5% crystal violet. Cell invasive ability was assessed by 6-well matrigel-coated transwell 
chambers (Corning Inc., Coring, USA) with 8-μm pore size as similar previous description. Triplicate experi-
ments were performed independently. The images were detected and analyzed by EVOS XL Core Imaging System 
(Invitrogen, Life Technologies, USA).
Western blottin. Total protein was extracted using RIPA lysis (Sigma, St. Louis, MO). Mitochondrial and 
cytosolic proteins were collected using Mitochondria/Cytosol Fractionation Kit (EMD Millipore, Massachusetts, 
USA) referring to manufacturer’s protocol. Cell lysates (20 μg) fractionated electrophoretically by 12% SDS-PAGE 
gels, and transferred onto PVDF membranes (GE Healthcare, Freiburg, DE). Primary antibodies against Bax, Bcl-
2, Caspase-9, Cyt C, PTEN, p-Akt (Ser473), Akt, p-GSK3β (Ser9), GSK3β, β-catenin and β-actin (Cell Signaling 
Technology, Danvers, MA) were probed with proteins on the membrane at 4 °C overnight. After incubating with 
secondary antibodies (Cell Signaling Technology, Danvers, MA), the results were detected by ECL Advance rea-
gent (GE Healthcare, Freiburg, DE) with ChemiDoc XRS System and analyzed by Image Lab Software (Bio-Rad, 
Kidlington, UK).
Immunohistochemistry analysis. Tumors were harvested from MMTV-PyMT transgenic mice at the end 
point of treatment. Paraffinized tumor sections were permeabilized in 0.2% Triton X-100 after de-paraffinized 
in xylene and rehydrated in ethanol. Tumor sections were immersed in sodium-citrate buffer (10 mM, pH 6.0) 
for antigen retrieval and blocked in 5% normal goat serum (Cell Signaling Technology, Danvers, MA). The 
slides were then incubated with diluted primary antibodies Bax, MMP-7, PTEN, and β-catenin (Cell Signaling 
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Technology, Danvers, MA) at 4 °C overnight. After washing, the slides were incubated with SignalStain Boost 
Detection Reagent (Cell Signaling Technology, Danvers, MA) and developed color according to SignalStain DAB 
Substrate Kit (Cell Signaling Technology, Danvers, MA) manufacturer’s guidelines. The study was conducted 
in accordance with the guidelines approved by Department of Health (Hong Kong, Ethic approval, 15–322). 
The images were detected by Leica DME microscope (Meyer Instruments, Inc., Houston, USA) and analyzed by 
ScopeImage 9.0 Image-Processing Software (BP Integrated Technologies, Inc., Calamba, PH).
Microarray analysis. Total RNA was extracted from 5 × 106 cells of MDA-MB-231 and MCF-7 cells with 
or without 24 h ISL treatment using RNAiso Plus reagent (TaKaRa Bio Inc., Shiga, JP). Microarray analysis was 
performed with the Affymetrix GeneChip Human Gene 2.0 ST array (Affymetrix, Santa Clara, CA) by the Centre 
for Genomic Sciences of HKU. The results were analyzed by 7.0 Partek Genomics Suite 6.6 software (Partek 
Incorporated, Missouri, USA).
Real-time RT–PCR. MiRNA was prepared using mirVana miRNA Isolation Kit (Ambion, Life Technologies, 
USA) and total RNA was prepared with RNAiso Plus reagent based on the manufacturer’s protocol. For miRNA 
reverse transcription, cDNA was synthesized using miRCURY LNA microRNA cDNA synthesis kit II (Exiqon, 
Vedbaek, DK). For mRNA reverse transcription, cDNA was synthesized using PrimeScript RT Reagent Kit with gDNA 
Eraser (TaKaRa Bio Inc., Shiga, JP). Real-time PCR for miRNA and RNA were performed using ExiLENT SYBR 
Green master mix (Exiqon, Vedbaek, DK) and SsoFast EvaGreen Supermixes (Bio-Rad, Kidlington, UK), respectively. 
Relative quantification was determined by normalization to GAPDH or U6. The primers are shown in Table S1.
In situ hybridization (ISH) analysis. Expression of miR-374a in formalin-fixed paraffin-embedded archive 
tissues tissues and normal tissues from 39 breast cancer patients (TMA) (US Biomax, Inc., Rockville, USA) col-
lected in 2004 was determined by ISH with probes for miR-374a. Each tissue spot was accompanied with cases 
material including sex, age, pathologic type, pathologic grade and clinical stage. The staining intensity was defined 
as described previously45. The study was conducted in accordance with the guidelines of Ethics Committee of Sun 
Yat-sen University Cancer Center (Guangzhou, China) and Tongxuxian People’s Hospital (Henan, China) (Ethic 
approval, 081116). A written informed consent was obtained from all participants involved in this study. The cor-
responding experimental protocols were approved by Ethics Committee of Sun Yat-sen University Cancer Center 
(Guangzhou, China). The images were detected by B203LED microscopy (Optec, Chongqing, CN) and analyzed 
by Image J (National Institutes of Health, Maryland, USA).
Cell transfection. Diluted RNA oligonucleotides of mirVana miRNA-374a mimic and mirVana miRNA 
Mimic Negative Control (Ambion, Life Technologies, USA) were mixed with diluted Lipofectamine RNAiMAX 
Transfection Reagent (Invitrogen, Life Technologies, USA) as 1:1 ratio and incubated for 5 minutes at room tem-
perature. The miRNA-lipid complex was then added to cells for 24 h transfection. Diluted RNA oligonucleotides 
of Silencer Select Negative Control PTEN siRNA and Silencer Select Negative Control siRNA (#4390843, Ambion, 
Life Technologies, USA) were mixed with diluted Lipofectamine 2000 Transfection Reagent (Invitrogen, Life 
Technologies, USA) as 1:1 ratio and incubated for 15 minutes at room temperature. The siRNA-lipid complex was 
then added to cells for 48 h transfection. The oligo sequences of siRNA PTEN are shown in Table S2.
Luciferase reporter assay. The amplified PTEN wide-type/mutant fragments were cloned into the Sac 
I and HindIII restriction sites of the pMIR-REPORT Luciferase plasmid (Ambion, Life Technologies, USA) 
using In-Fusion Dry-Down PCR Cloning Kit (TaKaRa Bio Inc., Shiga, JP). The primers are shown in Table S3. 
293 T cells were seeded into 96-well plates with transfection mixture. The luciferase activity was recorded using 
the Dual-Glo Luciferase Assay System (Promega, Madison, WI) by normalization to Renilla luciferase activity 
according to manufacturer’s instructions.
Statistical analysis. All the data were expressed as means ± standard deviations (SD). Two-tailed student’s 
t test, one way ANOVA, and Chi-square test were used to determine the significant difference of different exper-
iment results by 13.0 SPSS (SPSS Inc., Chicago, USA) software. Survival curves were plotted using the Kaplan–
Meier method. Data with P < 0.05 were considered as statistical significance.
Data availability. The datasets analyzed in Supplementary Fig. S3 during the current study are available in 
the array express repository, (https://www.ebi.ac.uk/arrayexpress/).
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